L. Eric Huang, MD, PhD

Research Interests

  • Genetic Instability
  • Molecular Targets
  • Brain Tumors
  • Mouse Models of Cancer
  • Hypoxia Inducible Factor-1
  • Cancer Biology

Languages

  • English

Academic Information

  • Departments: Neurosurgery - Associate Professor, Oncological Sciences - Adjunct Associate Professor
  • Divisions: Adult Neurosurgery
  • Cancer Center Programs: Nuclear Control of Cell Growth & Differentiation

Academic Office Information

  • 801-585-3221
  • Clinical Neurosciences Center
    175 North Medical Drive East, Room: 3335A
    Salt Lake City, UT 84132

Academic Bio

Eric Huang, MD, PhD, is an Associate Professor in the Department of Neurosurgery and an adjunct Associate Professor in the Department of Oncological Sciences in the School of Medicine at the University of Utah. He is an investigator in the Huntsman Cancer Institute and a member of the Nuclear Control of Cell Growth and Differentiation program. Dr. Huang received his MD degree from the Shanghai Medical University, Shanghai, China in 1984. Following this he was a resident in Tumor Pathology at the Cancer Hospital-Shanghai Medical University in China between1984-1986. He then went on to complete his Ph.D. in 1994, in the area of cell and developmental biology from Rutgers University. Dr. Huang received postdoctoral training at the Brigham and Women’s Hospital, Harvard Medical School as a Research Fellow between 1994-1997. Following this, for approximately three years, Dr. Huang stayed on as an Instructor in Medicine at Harvard Medical School. In 2000 Dr. Huang became a Principal Investigator at the National Institute of Health in Bethesda, MD and Head of the Hypoxia and Tumorigenesis Unit in the Laboratory of Carcinogenesis, National Cancer Institute, National Institutes of Health. His research focuses on the study of the hypoxic environment (low oxygen tension), in which many cancer cells survive, and how hypoxia can make cancer more aggressive.

Education History

Type School Degree
Postdoctoral Fellowship Harvard Medical School, Brigham & Women's Hospital
Molecular Biology
Postdoctoral Fellow
Doctoral Training Rutgers University
Cell and Developmental Biology
Ph.D.
Graduate Training Rutgers University
Biomedical Engineering
Residency Shanghai Medical University Cancer Hospital
Pathology
Resident
Professional Medical Shanghai Medical University
Medicine
M.D.

Global Impact

Education History

Type School Degree Country
Residency Shanghai Medical University Cancer Hospital
Pathology
Resident China
Professional Medical Shanghai Medical University
Medicine
M.D. China

Presentations

Description Country
Latest Understanding of Malignant Glioma, Nanchang Second Affiliate Hospital, Nanchang University, Nanchang, Jiangxi, China China
Latest Understanding of Malignant Glioma, People's Hospital of Shangrao City, Shangrao, Jiangxi, China China

Service

Date Role Description Country
08/28/2010 Committee Member Member of the Genomics and Biodiversity Commission for the 37th World Congress of International Union of Physiological Sciences Global
06/16/2015 Committee Member Member of the Genomics and Biodiversity Commission for the 38th World Congress of International Union of Physiological Sciences Global

Career

Institution Description Country
People's Hospital of Shangrao City Visiting Professor China
The Second Affiliated Hospital of Nanchang University Visting Professor China
The Affiliated People's Hospital of Jiangsu University VisitingProfessor China

Selected Publications

Journal Article

  1. Hayashi M, Yoo YG, Christensen J, Huang LE (2011). Requirement of evading apoptosis for HIF-1alpha-induced malignant progression in mouse cells. Cell Cycle, 10(14), 2364-72.
  2. Yoo YG, Christensen J, Gu J, Huang LE (2011). HIF-1{alpha} Mediates Tumor Hypoxia to Confer a Perpetual Mesenchymal Phenotype for Malignant Progression. Sci Signal, 4(178), pt4.
  3. Yoo YG, Christensen J, Huang LE (2011). HIF-1{alpha} Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function. Cancer Res, 71(4), 1244-52.
  4. Rice C, Huang LE (2010). From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res, 3, 9-16.
  5. Hammer S, To KK, Yoo YG, Koshiji M, Huang LE (2007). Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle, 6(15), 1919-26.
  6. To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE (2006). The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J, 25(20), 4784-94.
  7. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006). Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A, 103(49), 18727-32.
  8. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, Huang LE (2005). HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell, 17(6), 793-803.
  9. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R (2005). Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res, 65(8), 3299-306.
  10. To KK, Koshiji M, Hammer S, Huang LE (2005). Genetic instability: the dark side of the hypoxic response. Cell Cycle, 4(7), 881-2.
  11. To KK, Huang LE (2005). Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem, 280(45), 38102-7.
  12. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J, 23(9), 1949-56.
  13. Kageyama Y, Koshiji M, To KK, Tian YM, Ratcliffe PJ, Huang LE (2004). Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J, 18(9), 1028-30.
  14. Koshiji M, Huang LE (2004). Dynamic balancing of the dual nature of HIF-1alpha for cell survival. Cell Cycle, 3(7), 853-4.
  15. Huang LE, Pete EA, Schau M, Milligan J, Gu J (2002). Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. J Biol Chem, 277(44), 41750-5.
  16. Gu J, Milligan J, Huang LE (2001). Molecular mechanism of hypoxia-inducible factor 1alpha -p300 interaction. A leucine-rich interface regulated by a single cysteine. J Biol Chem, 276(5), 3550-4.
  17. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM (2001). Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev, 15(19), 2520-32.
  18. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2(7), 423-7.
  19. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF (1999). Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem, 274(13), 9038-44.
  20. Huang LE, Gu J, Schau M, Bunn HF (1998). Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. PNAS, 95(14), 7987-92.
  21. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM (1996). An essential role for p300/CBP in the cellular response to hypoxia. PNAS, 93(23), 12969-73.
  22. Huang LE, Arany Z, Livingston DM, Bunn HF (1996). Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem, 271(50), 32253-9.

Review

  1. Yoo YG, Hayashi M, Christensen J, Huang LE (2009). An essential role of the HIF-1alpha-c-Myc axis in malignant progression. [Review]. New York Academy of Sciences. Annals, 1177, 198-204.
  2. Huang LE (2008). Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. [Review]. Cell Death and Differentiation, 15(4), 672-7.
  3. Huang LE, Bindra RS, Glazer PM, Harris AL (2007). Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. [Review]. Journal of Molecular Medicine, 85(2), 139-48.
  4. Huang LE, Bunn HF (2003). Hypoxia-inducible factor and its biomedical relevance. [Review]. Journal of Biological Chemistry, 278(22), 19575-8.

Book Chapter

  1. Huang LE, Yoo YG, Koshiji M, To KKW (2011). Hypoxia inhibits DNA repair to promote malignant progression. In S. Vengrova (Ed.), DNA Repair and Human Health (pp. 339-348, Chapter 11). Rieka, Croatia: Intech.
  2. Huang LE, Bunn HF (1998). Regulation of hypoxia inducible factor 1 activity. In Lopez-Barneo J, Weik EK (Eds.), Oxygen regulation of ion channels and gene expression (pp. 101-112). New York, Futura.

Conference Proceedings

  1. Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Huang LE, Johnson R, Kaelin W Jr, Koch CJ, Maxwell P, Mitchell J, Neckers L, Powis G, Rajendran J, Semenza GL, Simon J, Storkebaum E, Welch MJ, Whitelaw M, Melillo G, Ivy SP (2004). Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Research, 64, 3350-3356.

Editorial

  1. Huang LE (2013). Biochemistry. How HIF-1alpha handles stress. Science, 339(6125), 1285-6.
  2. Johnson RS, Huang LE (2007). Can irradiated tumors take NO for an answer? Mol Cell, 26(2), 157-8.
  3. Huang LE (2004). Targeting HIF-alpha: when a magic arrow hits the bull's eye. Drug Discov Today, 9(20), 869.

Other

  1. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2005). A Novel HIF-1alpha-Myc Pathway Regulating Hypoxia-induced Cell-cycle Arrest. Frontiers In Science (May 2005, pp. 11-12). Bethesda: National Cancer Institute's Center for Cancer Research.
  2. Huang LE (2002). Leu574 of HIF-1alpha as a molecular basis for therapeutic development. Employee Invention Report.